In recent decades, prostate-specific antigen (PSA) testing has emerged as a widely used screening tool for prostate cancer (PC), yet its extensive use has inadvertently led to notable rates of PC overdiagnosis [1]. This evidence concerns the gene KLK3 and prostate carcinoma.